ERBB2 and breast carcinoma: In the PANACEA phase 1b/2 trial, HER2-positive breast cancer with a documented progression during previous trastuzumab-based therapy, a RECIST measurable disease and good PS, received a combination of pembrolizumab and trastuzumab [84].